Antimicrobial stewardship & healthcare epidemiology : ASHE最新文献

{"title":"Impact of an evidence-based order panel on antibiotic prescribing in ambulatory patients with cystitis.","authors":"Matt Neumann, Ryan W Stevens, Kristin Cole, Paschalis Vergidis, Abinash Virk, Dan Ilges, Kelsey L Jensen","doi":"10.1017/ash.2025.62","DOIUrl":"https://doi.org/10.1017/ash.2025.62","url":null,"abstract":"<p><strong>Background: </strong>Optimizing antibiotic prescribing for urinary tract infections (UTI) represents an opportunity for ambulatory antibiotic stewardship programs (ASPs). A pre-populated order panel for UTI was implemented in the Mayo Clinic Enterprise in May 2022. The order panel provides antibiotic regimens aligning with institutional guidelines according to patient characteristics, presence or absence of complicating features, and antimicrobial allergy status. We assessed impacts of panel use on prescribing practices for cystitis.</p><p><strong>Methods: </strong>This retrospective cohort study of ambulatory encounters with a primary diagnosis of cystitis from May 16, 2022, to May 15, 2023, compared encounters in which the order panel was utilized to encounters managed without the panel. The primary outcome was concordance with institutional guidelines, including drug selection, dose/frequency, and duration. Secondary outcomes included rate of repeat healthcare contact for UTI within 14 days and total duration of therapy.</p><p><strong>Results: </strong>793 randomly selected patient encounters (397 panel and 396 non-panel) were included. Prescribing was guideline adherent in 79.3% and 64.9% (<i>P</i> < 0.001) of panel and non-panel encounters, respectively. There were more 3- and 5-day treatment courses in the panel cohort; however, inappropriate duration of therapy was the most common reason for non-concordance in both cohorts. There was no significant difference between groups in repeat 14-day healthcare contact for UTI (13.4% panel vs 11.1% no panel, <i>P</i> = 0.34).</p><p><strong>Conclusion: </strong>Use of a pre-populated ambulatory order panel for the treatment of cystitis was associated with greater concordance with institutional guidelines, without adversely impacting repeat healthcare contact for UTI.</p>","PeriodicalId":72246,"journal":{"name":"Antimicrobial stewardship & healthcare epidemiology : ASHE","volume":"5 1","pages":"e96"},"PeriodicalIF":0.0,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12022930/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144061130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low- versus high-dose trimethoprim-sulfamethoxazole for the treatment of <i>Stenotrophomonas maltophilia</i> pneumonia.","authors":"Bradley Taranto, Lynn C Wardlow, Kelci Coe, Jose A Bazan, Jessica Leininger","doi":"10.1017/ash.2025.64","DOIUrl":"https://doi.org/10.1017/ash.2025.64","url":null,"abstract":"<p><strong>Objective: </strong>To compare outcomes of patients treated with low-dose (LD) versus high-dose (HD) trimethoprim-sulfamethoxazole (TMP-SMX) for <i>Stenotrophomonas maltophilia</i> pneumonia.</p><p><strong>Design: </strong>Retrospective cohort study.</p><p><strong>Setting: </strong>Large academic tertiary-care center.</p><p><strong>Patients: </strong>Hospitalized adult patients who received at least 8 mg/kg/day of TMP-SMX for at least 96 hours for treatment of <i>S. maltophilia</i> pneumonia between October 2012 and September 2022. Patients were included if they were diagnosed with pneumonia based on clinical and radiographic findings at the time of initiation of antibiotics.</p><p><strong>Methods: </strong>The primary outcome was clinical success at the end of therapy among patients treated with LD (8-12 mg/kg/day) versus HD (>12 mg/kg/day) TMP-SMX. Secondary outcomes included microbiological success, all-cause and infection-related inpatient mortality, infection recurrence, development of TMP-SMX resistance, and incidence of acute kidney injury (AKI) and hyperkalemia.</p><p><strong>Results: </strong>95 patients were included (LD, <i>n</i> = 20 versus HD, <i>n</i> = 75). There was no difference in the primary outcome of clinical success at the end of therapy between groups (LD 57% versus HD 65%, <i>P</i> = 0.53). Secondary outcomes, including inpatient infection-related mortality (<i>P</i> = 0.56), AKI (<i>P</i> = 0.61), and hyperkalemia (<i>P</i> = 0.34) also did not differ significantly between the LD and HD groups.</p><p><strong>Conclusions: </strong>No differences in clinical success or adverse events were observed in patients with <i>S. maltophilia</i> pneumonia treated with either LD or HD TMP-SMX.</p>","PeriodicalId":72246,"journal":{"name":"Antimicrobial stewardship & healthcare epidemiology : ASHE","volume":"5 1","pages":"e95"},"PeriodicalIF":0.0,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12022928/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144055113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Healthcare workers' attitudes and practices around environmental sustainability in infection prevention.","authors":"Ashley L Lin, Michelle E Doll, Rachel J Pryor, Elizabeth A Monsees, Priya Nori, Gonzalo M Bearman","doi":"10.1017/ash.2025.68","DOIUrl":"https://doi.org/10.1017/ash.2025.68","url":null,"abstract":"<p><p>We assessed healthcare workers' knowledge, attitudes, and practices around disposable personal protective equipment (PPE) use. We observed that healthcare workers are interested in sustainable policies and identified areas for policy changes to reduce PPE waste.</p>","PeriodicalId":72246,"journal":{"name":"Antimicrobial stewardship & healthcare epidemiology : ASHE","volume":"5 1","pages":"e94"},"PeriodicalIF":0.0,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12022923/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144042241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antibiotic use and financial impact of a comprehensive beta-lactam allergy management program.","authors":"Karan Raja, Lakhini Vyas, Susan Morrison, Donald Beggs, Mitesh Patel, Mona Philips","doi":"10.1017/ash.2025.36","DOIUrl":"https://doi.org/10.1017/ash.2025.36","url":null,"abstract":"<p><strong>Objective: </strong>A multidisciplinary beta-lactam allergy management program was implemented at our community medical center to facilitate allergy documentation, conduct penicillin skin testing (PST), and decrease non-beta-lactam (NBL) use. This study measures PST-associated antibiotic use and financial outcomes.</p><p><strong>Design: </strong>Cohort study.</p><p><strong>Setting: </strong>Non-teaching, urban, community medical center within a multi-hospital health system.</p><p><strong>Patients: </strong>Adult inpatients who underwent PST and received antibiotic therapy during a 5-year period at our facility.</p><p><strong>Methods: </strong>Demographics, allergies, laboratory results, PST outcome, and antimicrobial regimens were assessed. Actual NBL days of therapy (DOT) were collected from the electronic medical record. NBL DOT that patients would have received without PST were modeled by forecasting the original regimen to end of inpatient treatment. Difference between actual and forecasted DOT was deemed DOT avoided (DOT-A) for each consecutively enrolled patient. The financial analysis evaluated cumulative NBL cost avoided. PST outcomes and average time from antibiotic initiation to PST were assessed.</p><p><strong>Results: </strong>The study included 600 patients who underwent PST an average of 3.7 days into treatment. The most common indication was acute bacterial skin and skin structure infections (23.9%). PST results were negative in 98% of patients. NBL DOT-A was 944.8/1000DT (8.8 DOT-A per intervention) accounting for an estimated cost savings of $206,500 ($344.10 per intervention), driven primarily by aztreonam avoidance.</p><p><strong>Conclusions: </strong>This study highlights significant avoidance of NBL DOT in one of the largest identified cohort of inpatients undergoing PST. Associated cost avoidance contributes to the sustainability and longevity of the allergy management program.</p>","PeriodicalId":72246,"journal":{"name":"Antimicrobial stewardship & healthcare epidemiology : ASHE","volume":"5 1","pages":"e83"},"PeriodicalIF":0.0,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11986879/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144042365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-time biofluorescent particle counting compared to conventional air sampling for monitoring airborne contamination in orthopedic implant surgery.","authors":"Frans Stålfelt, Josefin Seth Caous, Karin Svensson Malchau, Camilla Björn, Maziar Mohaddes","doi":"10.1017/ash.2025.61","DOIUrl":"https://doi.org/10.1017/ash.2025.61","url":null,"abstract":"<p><strong>Background: </strong>Surgical site infection (SSI) following orthopedic surgery is a complication associated with morbidity and economic burden. Transmission of airborne bacteria that settle into surgical wounds constitutes a risk factor for SSIs. However, monitoring microbial contamination inside operating rooms with conventional methods is resource and time-consuming.</p><p><strong>Aim: </strong>This study aimed to assess correlation between a biofluorescent particle counter (BFPC) and conventional air sampling, to enable real-time monitoring of airborne contamination. Additionally, the study aimed to analyze correlation between particles near the surgical site and particles 1 meter away, to evaluate the feasibility of distance-based measurements.</p><p><strong>Methods: </strong>Correlation analysis was conducted to compare colony-forming units (CFU) collected using a Sartorius MD8 air sampler with biofluorescent viable particles detected by BioTrak 9510-BD, both positioned near the surgical site. Additionally, correlation between particle counts measured by AeroTrak 6510, positioned 1 meter away, and total particle counts measured by the BioTrak near the surgical site was evaluated. Sampling took place in two operating rooms: one with turbulent mixed airflow (TMA) and one with unidirectional airflow (UDAF).</p><p><strong>Results: </strong>Negligible to low correlation between biofluorescent particles and CFU was observed, both in UDAF (n = 100) and TMA (n = 22). However, strong correlation was found between BFPC and particle counter measurements of total numbers of particles (R_p = 0.634-0.769, <i>P</i> < .001).</p><p><strong>Conclusion: </strong>While BFPCs offer real-time monitoring of airborne contamination, their predictive ability for CFU levels remains uncertain. Yet, the strong correlation between particles in the surgical site and particles measured 1 meter away suggests feasibility to conduct future studies with larger cohorts.</p>","PeriodicalId":72246,"journal":{"name":"Antimicrobial stewardship & healthcare epidemiology : ASHE","volume":"5 1","pages":"e93"},"PeriodicalIF":0.0,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11986878/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144059763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revisiting restricted reproductive rights in 2025: what do we need to know now?","authors":"Pamela Bailey, Amy Crockett, Julie Ann Justo, Priya Nori","doi":"10.1017/ash.2025.56","DOIUrl":"https://doi.org/10.1017/ash.2025.56","url":null,"abstract":"<p><p>In the aftermath of the 2022 <i>Dobbs v Jackson Women's Health Organization</i> decision on access to reproductive healthcare, we published a commentary in this journal to inform the infectious diseases (ID) community about anticipated worsening of maternal and neonatal sepsis outcomes and relevant stewardship and healthcare associated infection issues. Three years later, we seek to keep the ID community engaged with important updates and intensify their commitment to providing high-quality care and reduce disparate health outcomes in this vulnerable population.</p>","PeriodicalId":72246,"journal":{"name":"Antimicrobial stewardship & healthcare epidemiology : ASHE","volume":"5 1","pages":"e92"},"PeriodicalIF":0.0,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11986880/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144029211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can we rely on artificial intelligence to guide antimicrobial therapy? A systematic literature review.","authors":"Sulwan AlGain, Alexandre R Marra, Takaaki Kobayashi, Pedro S Marra, Patricia Deffune Celeghini, Mariana Kim Hsieh, Mohammed Abdu Shatari, Samiyah Althagafi, Maria Alayed, Jamila I Ranavaya, Nicole A Boodhoo, Nicholas O Meade, Daniel Fu, Mindy Marie Sampson, Guillermo Rodriguez-Nava, Alex N Zimmet, David Ha, Mohammed Alsuhaibani, Boglarka S Huddleston, Jorge L Salinas","doi":"10.1017/ash.2025.47","DOIUrl":"https://doi.org/10.1017/ash.2025.47","url":null,"abstract":"<p><strong>Background: </strong>Artificial intelligence (AI) has the potential to enhance clinical decision-making, including in infectious diseases. By improving antimicrobial resistance prediction and optimizing antibiotic prescriptions, these technologies may support treatment strategies and address critical gaps in healthcare. This study evaluates the effectiveness of AI in guiding appropriate antibiotic prescriptions for infectious diseases through a systematic literature review.</p><p><strong>Methods: </strong>We conducted a systematic review of studies evaluating AI (machine learning or large language models) used for guidance on prescribing appropriate antibiotics in infectious disease cases. Searches were performed in PubMed, CINAHL, Embase, Scopus, Web of Science, and Google Scholar for articles published up to October 25, 2024. Inclusion criteria focused on studies assessing the performance of AI in clinical practice, with outcomes related to antimicrobial management and decision-making.</p><p><strong>Results: </strong>Seventeen studies used machine learning as part of clinical decision support systems (CDSS). They improved prediction of antimicrobial resistance and optimized antimicrobial use. Six studies focused on large language models to guide antimicrobial therapy; they had higher prescribing error rates, patient safety risks, and needed precise prompts to ensure accurate responses.</p><p><strong>Conclusions: </strong>AI, particularly machine learning integrated into CDSS, holds promise in enhancing clinical decision-making and improving antimicrobial management. However, large language models currently lack the reliability required for complex clinical applications. The indispensable role of infectious disease specialists remains critical for ensuring accurate, personalized, and safe treatment strategies. Rigorous validation and regular updates are essential before the successful integration of AI into clinical practice.</p>","PeriodicalId":72246,"journal":{"name":"Antimicrobial stewardship & healthcare epidemiology : ASHE","volume":"5 1","pages":"e90"},"PeriodicalIF":0.0,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11986881/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144054211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single-center retrospective evaluation of a polymerase chain reaction-based pneumonia panel on antibiotic therapy optimization at a community hospital.","authors":"Luke Manda, Anthony Wasielewski, Nishika Patel, Timothy P Gauthier","doi":"10.1017/ash.2025.57","DOIUrl":"https://doi.org/10.1017/ash.2025.57","url":null,"abstract":"<p><p>The implementation of a polymerase chain reaction-based pneumonia panel was associated with actionable results in 87% of 384 cases. In a population of mostly elderly non-intensive care unit patients with sputum samples, opportunities for antibiotic stewardship included streamlining for atypical bacteria, <i>Pseudomonas aeruginosa</i>, and methicillin-resistant <i>Staphylococcus aureus</i> coverage, with occasional opportunities to escalate antibiotic therapy.</p>","PeriodicalId":72246,"journal":{"name":"Antimicrobial stewardship & healthcare epidemiology : ASHE","volume":"5 1","pages":"e91"},"PeriodicalIF":0.0,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11986877/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144047314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Healing soles: a microbiology-driven electronic health record-algorithm and order set to decrease antipseudomonal use in diabetic foot infections, a retrospective, observational, quasi-experimental study.","authors":"Antoinette Marie Acbo, Naida Koura-Mola, Terrence McSweeney, Hongkai Bao, Mei Chang, Kelsie Cowman, Priya Nori, Yi Guo","doi":"10.1017/ash.2025.59","DOIUrl":"10.1017/ash.2025.59","url":null,"abstract":"<p><strong>Background: </strong>Antipseudomonal antibiotics are commonly prescribed for diabetic foot infections (DFI) at our institution despite a low local prevalence of <i>Pseudomonas aeruginosa</i>. A multidisciplinary team implemented a DFI electronic health record (EHR)-embedded treatment algorithm and order set.</p><p><strong>Methods: </strong>This multi-center, quasi-experimental study evaluated adults on antibiotics admitted for DFI to vascular surgery or medical units pre- and post-implementation of an EHR-embedded treatment algorithm and order set. Exclusion criteria: duplicate patients, concomitant infection, transfer from an outside hospital. Primary endpoint: antipseudomonal use among included patients (DOT/1000 DFI days present). Secondary outcomes: empiric antipseudomonal use, length of stay, 30-day readmission, mortality, amputation, and <i>Clostridioides difficile</i> infection. Patient demographics, diagnostics, treatments, and outcomes were evaluated.</p><p><strong>Results: </strong>Two hundred ten patients were included with 70 patients included in each group. The post-algorithm group had lower antipseudomonal DOT/1000 DFI days present compared to the pre-intervention group (360 vs 503, <i>P</i> < 0.001). The post-order set group had the lowest antipseudomonal use (347 vs 503, <i>P</i> < 0.001). Empiric antipseudomonal use decreased from 85.7% pre-intervention to 72% post-algorithm and 68.5% post-order set. Collectively, 30-day mortality was < 5%. Amputation during and within 30 days of hospitalization was similar in the pre-intervention (48.6%), post-algorithm (30%), and post-order set (41.4%) groups. Methicillin-susceptible <i>Staphylococcus aureus</i> and <i>Streptococcus</i> spp. were most frequently isolated. Wound cultures were not collected in 24.3%, 22.9%, and 40% of the pre-intervention, post-algorithm, and post-order set group.</p><p><strong>Conclusions: </strong>EHR-embedded clinical decision-making tools reduce antipseudomonal use for DFI treatment without increasing 30-day mortality or amputation.</p>","PeriodicalId":72246,"journal":{"name":"Antimicrobial stewardship & healthcare epidemiology : ASHE","volume":"5 1","pages":"e89"},"PeriodicalIF":0.0,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11951233/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143756171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the evolution of <i>Acinetobacter baumannii</i> and <i>Pseudomonas aeruginosa</i> resistance during the COVID-19 era.","authors":"Emine Sehmen, Esmeray Mutlu Yılmaz, Sevim Yetkin Pusa, Metin Özdemir, Yavuz Yiğit","doi":"10.1017/ash.2025.46","DOIUrl":"10.1017/ash.2025.46","url":null,"abstract":"<p><strong>Aim: </strong>In our study, we aim to compare the resistance profiles of <i>Acinetobacter baumannii</i> and <i>Pseudomonas aeruginosa</i> isolates from intensive care unit (ICU) patients before and during the COVID-19 pandemic.</p><p><strong>Materials: </strong>The study involved adult patients monitored in the ICUs of a secondary-level hospital from January 2019 to December 2022. Isolates of <i>A. baumannii</i> and <i>P. aeruginosa</i> were obtained from blood, urine, and respiratory samples. Identification and antibiotic susceptibility tests were conducted using the disk diffusion method and the VITEK 2 system.</p><p><strong>Results: </strong>The average age of the patients was 61.3 ± 21.9 years (range: 18-95), with a majority of 1306 (51.6%) being male. During the pandemic, <i>A. baumannii</i> isolates showed a significant increase in resistance rates for several antibiotics compared to the pre-pandemic period: imipenem (96% vs 35.1%), amikacin (84.1% vs 14.4%), ciprofloxacin (96.9% vs 36.9%), trimethoprim-sulfamethoxazole (66.4% vs 27%), and ceftazidime (96.5% vs 33.3%) (all with <i>P</i> < .001). However, there was no significant change in colistin resistance rates in these isolates (0.9% vs 0%; <i>P</i> = .307). Similarly, <i>Pseudomonas aeruginosa</i> isolates exhibited significant increases in resistance rates during the pandemic compared to the pre-pandemic period: imipenem (51.5% vs 18.8%; <i>P</i> < .001), colistin (4.9% vs 0.6%; <i>P</i> = .009), amikacin (23.5% vs 4.4%; <i>P</i> < .001), ciprofloxacin (53.3% vs 13.8%; <i>P</i> < .001), and ceftazidime (39.2% vs 12.7%; <i>P</i> < .001).</p><p><strong>Conclusion: </strong>Our results demonstrate a significant increase in antibiotic resistance levels in <i>Acinetobacter</i> and <i>Pseudomonas</i> strains associated with hospital-acquired infections or colonization during the COVID-19 pandemic.</p>","PeriodicalId":72246,"journal":{"name":"Antimicrobial stewardship & healthcare epidemiology : ASHE","volume":"5 1","pages":"e88"},"PeriodicalIF":0.0,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11951232/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143756169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}